VEGFA and hereditary hemorrhagic telangiectasia: Since 2012, following two promising case reports [50, 51], anti-angiogenic treatment using Bevacizumab, a humanized monoclonal antibody that selectively binds to and neutralizes the biologic activity of human VEGF, was tested on HHT patients in several clinical trials.